...
首页> 外文期刊>The Pediatric infectious disease journal >Treatment of fast breathing in neonates and young infants with oral amoxicillin compared with penicillin-gentamicin combination: study protocol for a randomized, open-label equivalence trial.
【24h】

Treatment of fast breathing in neonates and young infants with oral amoxicillin compared with penicillin-gentamicin combination: study protocol for a randomized, open-label equivalence trial.

机译:与青霉素-庆大霉素联用相比,口服阿莫西林治疗新生儿和婴儿的快速呼吸:一项随机,开放标签等效试验的研究方案。

获取原文
获取原文并翻译 | 示例
           

摘要

The World Health Organization recommends hospitalization and injectable antibiotic treatment for young infants (0-59 days old), who present with signs of possible serious bacterial infection. Fast breathing alone is not associated with a high mortality risk for young infants and has been treated with oral antibiotics in some settings. This trial was designed to examine the safety and efficacy of oral amoxicillin for young infants with fast breathing compared with that of an injectable penicillin-gentamicin combination. The study is currently being conducted in the Democratic Republic of Congo, Kenya and Nigeria.This is a randomized, open-label equivalence trial. All births in the community are visited at home by trained community health workers to identify sick infants who are then referred to a trial study nurse for assessment. The primary outcome is treatment failure by day 8 after enrollment, defined as clinical deterioration, development of a serious adverse event including death, persistence of fast breathing by day 4 or recurrence up to day 8. Secondary outcomes include adherence to study therapy, relapse, death between days 9 and 15 and adverse effects associated with the study drugs. Study outcomes are assessed on days 4, 8, 11 and 15 after randomization by an independent outcome assessor who is blinded to the treatment being given.The results of this study will help inform the development of policies for the treatment of fast breathing among neonates and young infants in resource-limited settings.
机译:世界卫生组织建议对表现出严重细菌感染迹象的婴儿(0-59天大)进行住院治疗和注射抗生素治疗。单独的快速呼吸与婴儿的高死亡风险无关,并且在某些情况下已经接受口服抗生素治疗。该试验旨在检查口服阿莫西林与青霉素-庆大霉素注射剂相比,对呼吸急促的婴儿的安全性和有效性。这项研究目前正在刚果民主共和国,肯尼亚和尼日利亚进行,这是一项随机的,开放标签的等效试验。经过培训的社区卫生工作者在家中探访社区中的所有婴儿,以识别患病的婴儿,然后将其转介给试验研究护士进行评估。主要结局是入选后第8天治疗失败,定义为临床恶化,严重的不良事件(包括死亡),第4天持续快速呼吸或直到第8天复发。次要结局包括坚持研究治疗,复发,第9天到15天之间的死亡以及与研究药物相关的不良反应。研究结果在随机分配后的第4、8、11和15天由独立的结果评估者评估,该评估者对正在接受的治疗不知情。这项研究的结果将有助于制定新生儿和新生儿快速呼吸治疗政策。在资源有限的环境中的幼儿。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号